問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberTL-895-201

2021-09-01 - 2025-08-31

Phase II

Recruiting5

ICD-10D47.4

Osteomyelofibrosis

ICD-10D68.51

Activated protein C resistance

ICD-10D68.52

Prothrombin gene mutation

ICD-10D68.59

Other primary thrombophilia

ICD-10D68.61

Antiphospholipid syndrome

ICD-10D68.62

Lupus anticoagulant syndrome

ICD-10D68.69

Other thrombophilia

ICD-10D75.81

Myelofibrosis

ICD-10D75.89

Other specified diseases of blood and blood-forming organs

ICD-10D77

Other disorders of blood and blood-forming organs in diseases classified elsewhere

ICD-10D89.2

Hypergammaglobulinemia, unspecified

ICD-10E88.09

Other disorders of plasma-protein metabolism, not elsewhere classified

ICD-9289.8

Other specified diseases of blood and blood-forming organs

  • Trial Applicant

    MEDPACE TAIWAN LIMITED

  • Sponsor

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2025/08/20

Investigators and Locations

Principal Investigator Su-Peng Yeh Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 王銘崇 Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Hui-Hua Hsiao Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator HSIN-AN HOU Division of General Internal Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 陳志丞 Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Condition/Disease

Objectives

Test Drug

Active Ingredient

Dosage Form

Dosage

Endpoints

Inclution Criteria

The Estimated Number of Participants

  • Taiwan

    10 participants

  • Global

    181 participants